Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilhem Roubaud

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
European Urology|April 25, 2022
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysisPawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al.
Clinical Genitourinary Cancer|October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
Lancet (London, England)|April 11, 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designKarim Fizazi, Stéphanie Foulon, Joan Carles, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
European Urology|April 25, 2022
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysisPawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al.
Clinical Genitourinary Cancer|October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
Lancet (London, England)|April 11, 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designKarim Fizazi, Stéphanie Foulon, Joan Carles, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Pageof 10